Channing Der guides the Guardian through the history of the "Undruggable RAS Mutation."
Nate Diehl Awarded at Postdoc Day
Der Lab member, Nate Diehl, recently attended the 45th Annual Postdoc Faculty Research Day-- a symposium run primarily by the ITCMS Postdoc trainees and welcome to all of UNC Lineberger trainees and graduate students. Nate was awarded for Best Graduate Student Poster. He presented on Life without KRAS: profiling the KRAS-dependent kinome to identify novel therapeutic vulnerabilities … Continue reading Nate Diehl Awarded at Postdoc Day
Priya Hibshman Presents
Der lab member, Priya Hibshman will present at the Cell Biology and Physiology Fusion Seminar on Monday, November 16th at 12:00 pm ET. She will present on Determining the role of MYC in KRAS-mutant pancreatic cancer." Come out to support Priya! https://zoom.us/j/93528847652?pwd=UUMzVVA3dDZORytSdUM2WUEvYnNqQT09 Meeting ID: 935 2884 7652 Passcode: 056819
Researchers find KRAS gene mutation differences have implications for pancreatic cancer treatment
A new study from University of North Carolina Lineberger Comprehensive Cancer Center researchers reveals important findings about how a common genetic mutation in pancreatic cancer works to drive tumor growth. In the journal Cancer Discovery, researchers led by UNC Lineberger’s Channing Der, PhD, and Aaron Hobbs, PhD, reported details of the role of a particular mutation … Continue reading Researchers find KRAS gene mutation differences have implications for pancreatic cancer treatment
Channing Der Quoted by Bloomberg
Right DirectionThe findings follow data this summer that showed half of those treated with Amgen’s drug at a wide range of doses responded. The latest results more than doubled the number of patients treated with the highest dose and tracked them for three more months. It’s too early to know how long the benefits will last and … Continue reading Channing Der Quoted by Bloomberg
Der Lab Blue Ribbon Tour 2019
August 5, 2019 Today, the Der and Cox labs were visited by the Blue Ribbon group of Wilmington, NC. The Blue Ribbon Run raises money for the Julie M. Brown and Christina M. Gianoplus Fund for Colon Cancer Research from Wilmington, NC. Members of the group included Ana Boudreau, event founder, and Sarah Powell, a … Continue reading Der Lab Blue Ribbon Tour 2019
UNC Lineberger Writes: Researchers identify resistance mechanism to possible pancreatic cancer treatment
In the journal Cancer Cell, UNC Lineberger's Channing Der, PhD, and colleagues described how pancreatic cancer may develop resistance to ERK inhibitors in pancreatic cancer. November 16, 2018 Despite decades of research, treatments that can target a common mutation in the most frequently diagnosed type of pancreatic cancer have remained elusive. Now, University of North … Continue reading UNC Lineberger Writes: Researchers identify resistance mechanism to possible pancreatic cancer treatment
‘Cracking the Nut’ on RAS Mutations
Scientists have spent 35 years seeking ways to disable RAS, a gene that’s mutated in many cancer types. Now, they’re moving closer to solutions. An article by TARA HAELLE PUBLISHED August 03, 2018 The fact that JOHN MACLEOD'S colorectal cancer expresses a RAS gene mutation has limited his treatment options. - PHOTO BY KONNOR J … Continue reading ‘Cracking the Nut’ on RAS Mutations
George and Huynh were authors on a research study that evaluated the role of posttranslational modifications in regulating KRAS oncogene function.
Abstract The KRAS GTPase plays a critical role in control of cellular growth. The activity of KRAS is regulated by guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs), and also by posttranslational modification. Lysine 104 in KRAS can be modified by ubiquitylation and acetylation, but the role this residue in intrinsic KRAS function has not … Continue reading George and Huynh were authors on a research study that evaluated the role of posttranslational modifications in regulating KRAS oncogene function.
Promising direction for the treatment of pancreatic cancers driven by KRAS mutation
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found a promising strategy that may limit the growth of pancreatic cancers in patients with a mutation in a gene called KRAS. More than 95 percent of pancreatic cancers have KRAS mutations, and there's strong evidence that blocking the gene's function could be a very … Continue reading Promising direction for the treatment of pancreatic cancers driven by KRAS mutation